These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Trends and outcomes in allogeneic hematopoietic stem cell transplant for multiple myeloma at Mayo Clinic. Mir MA; Kapoor P; Kumar S; Pandey S; Dispenzieri A; Lacy MQ; Dingli D; Hogan W; Buadi F; Hayman S; Gandhi M; Gertz MA Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):349-357.e2. PubMed ID: 25958193 [TBL] [Abstract][Full Text] [Related]
24. 18F-3'-Deoxy-3'-Fluorothymidine Positron Emission Tomography Imaging for the Prediction of Acute Graft-Versus-Host Disease in Mouse Hematopoietic Stem Cell Transplant Models. Lee YZ; Akinnagbe-Zusterzeel E; Fowler KA; Coghill JM Biol Blood Marrow Transplant; 2018 Nov; 24(11):2184-2189. PubMed ID: 29981461 [TBL] [Abstract][Full Text] [Related]
25. Intestinal Microbiota Can Predict Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation. Han L; Zhang H; Chen S; Zhou L; Li Y; Zhao K; Huang F; Fan Z; Xuan L; Zhang X; Dai M; Lin Q; Jiang Z; Peng J; Jin H; Liu Q Biol Blood Marrow Transplant; 2019 Oct; 25(10):1944-1955. PubMed ID: 31299215 [TBL] [Abstract][Full Text] [Related]
26. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease. Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664 [TBL] [Abstract][Full Text] [Related]
27. Diarrhea during the conditioning regimen is correlated with the occurrence of severe acute graft-versus-host disease through systemic release of inflammatory cytokines. Liu D; Yan C; Xu L; Wang Y; Han W; Zhang X; Liu K; Huang X Biol Blood Marrow Transplant; 2010 Nov; 16(11):1567-75. PubMed ID: 20546909 [TBL] [Abstract][Full Text] [Related]
28. Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results. Koreth J; Kim HT; Lange PB; Poryanda SJ; Reynolds CG; Rai SC; Armand P; Cutler CS; Ho VT; Glotzbecker B; Yusuf R; Nikiforow S; Chen YB; Dey B; McMasters M; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP Haematologica; 2018 Mar; 103(3):522-530. PubMed ID: 29326124 [TBL] [Abstract][Full Text] [Related]
29. Endothelial microparticles delivering microRNA-155 into T lymphocytes are involved in the initiation of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Zhang R; Wang X; Hong M; Luo T; Zhao M; Shen H; Fang J; Li X; Zang S; Chen P; Nie D; Zheng P; Wu Q; Xia L Oncotarget; 2017 Apr; 8(14):23360-23375. PubMed ID: 28423578 [TBL] [Abstract][Full Text] [Related]
30. Cyclosporine levels > 195 μg/L on day 10 post-transplant was associated with significantly reduced acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Bianchi M; Heim D; Lengerke C; Halter J; Gerull S; Kleber M; Tsakiris DA; Passweg J; Tzankov A; Medinger M Ann Hematol; 2019 Apr; 98(4):971-977. PubMed ID: 30542943 [TBL] [Abstract][Full Text] [Related]
31. Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients. Caballero-Velázquez T; López-Corral L; Encinas C; Castilla-Llorente C; Martino R; Rosiñol L; Sampol A; Caballero D; Serrano D; Heras I; San Miguel J; Pérez-Simón JA Br J Haematol; 2013 Aug; 162(4):474-82. PubMed ID: 23772672 [TBL] [Abstract][Full Text] [Related]
32. Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma. Kikuchi T; Mori T; Koda Y; Kohashi S; Kato J; Toyama T; Nakazato T; Aisa Y; Shimizu T; Okamoto S Int J Hematol; 2015 Dec; 102(6):670-7. PubMed ID: 26440970 [TBL] [Abstract][Full Text] [Related]
33. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease. Zhao L; Chen S; Yang P; Cao H; Li L Stem Cell Res Ther; 2019 Jun; 10(1):182. PubMed ID: 31227011 [TBL] [Abstract][Full Text] [Related]
35. Novel approaches for preventing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Servais S; Beguin Y; Delens L; Ehx G; Fransolet G; Hannon M; Willems E; Humblet-Baron S; Belle L; Baron F Expert Opin Investig Drugs; 2016 Aug; 25(8):957-72. PubMed ID: 27110922 [TBL] [Abstract][Full Text] [Related]
36. The expression of Th17-associated cytokines in human acute graft-versus-host disease. Liu Y; Cai Y; Dai L; Chen G; Ma X; Wang Y; Xu T; Jin S; Wu X; Qiu H; Tang X; Li C; Sun A; Wu D; Liu H Biol Blood Marrow Transplant; 2013 Oct; 19(10):1421-9. PubMed ID: 23792271 [TBL] [Abstract][Full Text] [Related]
37. Post-Transplantation Natural Killer Cell Count: A Predictor of Acute Graft-Versus-Host Disease and Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation. Kim SY; Lee H; Han MS; Shim H; Eom HS; Park B; Kong SY Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):527-535.e2. PubMed ID: 27375156 [TBL] [Abstract][Full Text] [Related]
38. The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review. Chaudhry HM; Bruce AJ; Wolf RC; Litzow MR; Hogan WJ; Patnaik MS; Kremers WK; Phillips GL; Hashmi SK Biol Blood Marrow Transplant; 2016 Apr; 22(4):605-616. PubMed ID: 26409924 [TBL] [Abstract][Full Text] [Related]